First Time Loading...

Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73%
Updated: May 7, 2024

Amryt Pharma Holdings Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amryt Pharma Holdings Ltd
Revenue Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Amryt Pharma Holdings Ltd
LSE:AMYT
Revenue
$182.6m
CAGR 3-Years
131%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Revenue
£30.7B
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
2%
AstraZeneca PLC
LSE:AZN
Revenue
$47.6B
CAGR 3-Years
20%
CAGR 5-Years
16%
CAGR 10-Years
6%
Indivior PLC
LSE:INDV
Revenue
$1.1B
CAGR 3-Years
19%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Revenue
$2.9B
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
8%
Dechra Pharmaceuticals PLC
LSE:DPH
Revenue
£761.5m
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
15%

See Also

What is Amryt Pharma Holdings Ltd's Revenue?
Revenue
182.6m USD

Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Revenue amounts to 182.6m USD.

What is Amryt Pharma Holdings Ltd's Revenue growth rate?
Revenue CAGR 3Y
131%

Over the last year, the Revenue growth was 214%. The average annual Revenue growth rates for Amryt Pharma Holdings Ltd have been 131% over the past three years .